Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Regulatory Routine +

Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development

Psychedelic GMP manufacturer advances ibogaine development amid US policy tailwinds, but commercial revenue remains negligible.

By The Northwire Desk — AI Analysis Jun 08, 2026 · 08:00 OPTI · 6.5 Optimi Health Corp.
Executive Summary
  • Optimi Health Corp. secured naturally derived ibogaine in hydrochloride and freebase forms from two sources.
  • Finished drug product development for 50mg and 100mg encapsulated formats will commence this summer at its Canadian GMP facility.
  • The development program covers SOPs, manufacturing validation, and analytical testing for encapsulation, bottling, labeling, and packaging.
  • The update follows a U.S. Executive Order (April 18, 2026) prioritizing ibogaine for accelerated FDA review and expanded patient access, with federal funding directed to match state investments.
  • Ibogaine is not a controlled substance in Canada (regulated under the Food and Drugs Act), contrasting with its Schedule I status in the United States.
  • Clinical indications under investigation include PTSD, opioid use disorder, and traumatic brain injury (TBI).
  • The company's Canadian GMP facility also manufactures psilocybin and MDMA for clinical research and regulated patient access.
  • A progress update will be provided upon completion of the in-house development program.
Material Impact
  • The announcement represents an operational milestone rather than a financial inflection point. It confirms execution on the "Ibogaine Initiative" launched in April 2026.
  • No revenue, pricing, or contract values are disclosed. The company is in the pre-clinical/development phase for this new product line.
  • The U.S. Executive Order provides a favorable policy backdrop, but it is non-binding and does not guarantee FDA approval or reimbursement pathways. Ibogaine remains Schedule I in the U.S., meaning commercial sales are still years away.
  • The news does not alter the company's immediate cash burn or near-term revenue trajectory. It is a strategic positioning move to capture future demand in a nascent market.
OPTI · Price
Company Overview
  • Optimi Health Corp. is a vertically integrated, Health Canada-licensed GMP manufacturer specializing in controlled psychedelic substances.
  • Core products include MDMA (for PTSD) and naturally derived psilocybin (for treatment-resistant depression), manufactured at two 10,000 sq ft facilities in British Columbia.
  • The company has a commercial footprint in Australia under the Therapeutic Goods Administration's Authorized Prescriber Scheme, with reimbursement from public and private payers.
  • It also supplies GMP-grade finished drug products and APIs for clinical research globally, including trials in Israel, the U.S., and Europe.
  • The company recently uplisted to the Nasdaq Capital Market (ticker: OPTH) following a $15M USD public offering and a 1-for-30 reverse stock consolidation.
Read the original news release →

More from Optimi Health Corp.

Jun 29, 2026 · 09:00

Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression

Production / Operations Jun 16, 2026 · 08:30

Vertically integrated GMP psychedelic manufacturer scaling clinical supply, but revenue remains negligible and execution is incremental.

Production / Operations Jun 10, 2026 · 09:15

Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial

Production / Operations Jun 02, 2026 · 07:30

Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia

Production / Operations May 29, 2026 · 08:30

Australia widens insurance-backed psychedelic therapy access — Optimi’s existing supply chain gains yet another tailwind, but market still awaits proof-of-revenue.

Regulatory May 26, 2026 · 07:01

Optimi Health Manufacturing Milestone Validates Capital Raise But Nasdaq Uplifting Remains Primary Valuation Driver

Production / Operations